Discussion
Dupilumab is an injectable humanized IgG4 monoclonal antibody, approved
for home use in patients with eosinophilic or steroid dependent asthma,
which targets IL-4α receptors and inhibits IL-4 and IL-13 binding. It
has been shown to reduce the frequency of asthma exacerbations, improve
FEV1 and reduce oral steroid use in patients with severe
asthma5. This is the first report of dupilumab as a
therapy to treat CEP and the first report of monoclonal antibody therapy
to treat CEP in a pediatric patient. Dupilumab may be an alternative for
CEP that is refractory to corticosteroids or that requires prolonged
therapy. It may also be a more convenient therapy compared to other
monoclonal antibodies available to patients because it can be
administered at home.